Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BTCY
Biotricity Inc. (BTCY) P/E ratio
Biotricity Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RBOT Vicarious Surgical Inc. compare | n/m |
| BTCY Biotricity Inc. | n/m |
| SINT SINTX TECHNOLOGIES, INC. compare | n/m |
| CTSO Cytosorbents Corporation compare | n/m |
| AEMD Aethlon Medical, Inc. compare | n/m |
| BMRA Biomerica, Inc. compare | n/m |
| IRIX IRIDEX Corporation compare | n/m |
| NMTC NeuroOne Medical Technologies Corporation compare | n/m |
| PETV PetVivo Holdings, Inc. compare | n/m |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)